As DCAF7 has been implicated in regulating drug sensitivity in pancreatic neuroendocrine tumors and nasopharyngeal carcinoma [1, 2], we sought to investigate its potential involvement in modulating sorafenib response in HCC. Here, DCAF7 is linked to pancreatic neuroendocrine tumor.